US › Healthcare

Kyntra Bio, Inc. (KYNB)

US · Healthcare · Biotechnology

$3.73+1.91%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$-1.5M

Revenue YoY

-209.3%

Net profit

$12.0M

EPS

$-4.68

EPS estimate

$-3.18

EPS came in at -4.68 against a street estimate of -3.18 — a miss of 47.2%.

Key statistics

Market cap

$14.8M

Forward P/E

61.3

P/B

80.40

Book value

$-7.45

EPS (TTM)

$-7.64

52-week high

$11.19

52-week low

$3.60

50-day MA

$6.47

200-day MA

$7.03

Beta

1.10

Analyst view

Analysts rate Kyntra Bio, Inc. a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $38.50.

Shareholding

Insiders

2.02%

Institutions

24.67%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.88%
Vanguard Capital Management, LLC	3.95%
Acadian Asset Management LLC	2.61%
BlackRock Inc	2.08%
Geode Capital Management, LLC	1.07%
HighTower Advisors, LLC	0.98%
Two Sigma Investments LLC	0.98%
Renaissance Technologies Corp	0.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kyntra Bio, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.